The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | NICE approves acalabrutinib for CLL in the UK
Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, talks on the NICE approval of the Bruton’s tyrosine kinase inhibitor acalabrutinib for patients with chronic lymphocytic leukemia (CLL) in the UK, commenting on implications for clinical practice. Dr Eyre reports that the biggest impact of the approval will be in the front-line setting. Dr Eyre also highlights the approval of venetoclax in combination with obinutuzumab for patients with CLL.
